Advertisement

Opioids pp 279-293 | Cite as

Selective Nonpeptide Opioid Antagonists

  • P. S. Portoghese
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 104 / 1)

Abstract

Opioid antagonists have been indispensable as tools in opioid research (Zimmerman and Leander 1990). In fact, the chief criterion for the classification of an agonist effect as opioid receptor-mediated is the ability of naloxone (Sawynok et al. 1979) or naltrexone (Gold et al. 1982) to reversibly antagonize this effect in a competitive fashion. The usefulness of these ligands for this purpose stems from the fact that they are universal opioid antagonists; that is, they are capable of antagonizing the agonist effects mediated by multiple opioid receptor types.

Keywords

Opioid Receptor Opioid Peptide Opioid Antagonist Opioid Agonist Opioid Receptor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belleney J, Gacel G, Fournie-Zaluski MC, Maigret B, Roques BP (1989) δ opioid receptor selectivity induced by conformational constraints in linear enkephalin- related peptides: 1H 400-MHz NMR study and theoretical calculations. Biochemistry 28:7392–7400PubMedCrossRefGoogle Scholar
  2. Birch PJ, Hayes AG, Sheehan MJ, Tyers MB (1987) Norbinaltorphimine: antagonist profile at K opioid receptors. Eur J Pharmacol 144: 405–408PubMedCrossRefGoogle Scholar
  3. Burgen ASV, Roberts GCK, Feeny J (1975) Binding of flexible ligands to macromolecules. Nature 253: 753–755PubMedCrossRefGoogle Scholar
  4. Chavkin C, Goldstein A (1981) Specific receptor for the opioid peptide dynorphin. Proc Natl Acad Sci USA 78: 6543–6547PubMedCrossRefGoogle Scholar
  5. Cotton R, Giles MG, Miller L, Shaw JS, Timms D (1984) A highly selective antagonist for the delta receptor. Eur J Pharmacol 97: 331–332PubMedCrossRefGoogle Scholar
  6. Cruciani RA, Lutz RA, Munson PJ, Rodbard D (1987) Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu-2, and delta opioid binding sites in rat brain membranes. J Pharmacol Exp Ther 242: 15–20PubMedGoogle Scholar
  7. Endoh T, Koike H, Matsura H, Nagase H (1990) Nor-binaltorphimine (nor-BNI); a potent and selective kappa opioid receptor antagonist with ultralong-lasting activity in vivo. In: van Ree JM, Mulder AH, Wiegant VM, van Wimersma Greidanus TB (eds) New leads in opioid research. Excerpta Medica, Amsterdam, pp 82–83Google Scholar
  8. Erez M, Takemori AE, Portoghese PS (1982) Narcotic antagonistic potency of bivalent ligands which contain β-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem 25: 847–849PubMedCrossRefGoogle Scholar
  9. Fournie-Zaluski M-C, Gacel G, Maigret B, Premilat S, Roques BP (1981) Structural requirements for specific recognition of μ or δ opiate receptors. Mol Pharmacol 20: 484–491PubMedGoogle Scholar
  10. Garzon-Aburbeh A, Lipkowski AW, Larson DL, Portoghese PS (1989) Transfer of fatty acyl groups from membrane phospatides to opiate ligands. Neurochem Int 15: 207–214PubMedCrossRefGoogle Scholar
  11. Gold MS, Dackis CA, Pottash ALC, Sternbach HH, Annetto WJ, Martin D, Dakis MP (1982) Naltrexone, opiate addiction, and endorphins. Med Res Rev 2: 211–246PubMedCrossRefGoogle Scholar
  12. Herz A (1987) The multiplicity of opioid receptors and their functional significance. In: Mutschler E, Winterfeldt E (eds) Trends in medicinal chemistry. VCH, Weinheim, pp 337–350Google Scholar
  13. Hruby VJ, Gehrig CA (1989) Recent developments in the design of receptor specific opioid peptides. Med Res Rev 9: 343–401PubMedCrossRefGoogle Scholar
  14. Iijima I, Minamikawa J, Jacobson AE, Brossi A, Rice K, Klee WA (1978) Studies in the (+)-morphinan series: 5. Synthesis and biological properties of (+)-naloxone. J Med Chem 21: 398–400Google Scholar
  15. Ishida T, Yoneda S, Doi M, Inoue M, Kitamura K (1988) Molecular-dynamics simulations of [Met5]- and [D-Ala2,Met5]-enkephalins. Biochem J 255: 621–628PubMedGoogle Scholar
  16. Jacob JJC, Ramabadran K (1977) Opioid antagonists, endogenous ligands and antinociception. Eur J Pharmacol 46: 393–394PubMedCrossRefGoogle Scholar
  17. Johnson N, Pasternak GW (1984) Binding of [3H]naloxonazine to rat brain membranes. Mol Pharmacol 26: 477–483PubMedGoogle Scholar
  18. Kawai H, Kikuchi T, Okamoto Y (1989) A prediction of tertiary structures of peptide by the Monte Carlo simulated annealing method. Protein Eng 3: 85–94PubMedCrossRefGoogle Scholar
  19. Ling GSF, Simantov R, Clark JA, Pasternak GW (1986) Naloxonazine actions in vivo. Eur J Pharmacol 129: 33–38PubMedCrossRefGoogle Scholar
  20. Lipkowski AW, Tam SW, Portoghese PS (1986) Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem 29: 1222–1225PubMedCrossRefGoogle Scholar
  21. Michne WF, Lewis TR, Michalec SJ, Pierson AK, Gillan MGC, Paterson SJ, Robson LE, Kosterlitz HW (1978) Novel developments of N-methylbenzomorphan narcotic antagonists. In: Van Ree JM, Terenius L (eds) Characteristics and functions of opioids. Elsevier, Amsterdam, pp 197–206Google Scholar
  22. Olson GA, Olson RD, Kastin AJ (1989) Endogenous opiates: 1987. Peptides 10: 205–236PubMedCrossRefGoogle Scholar
  23. Pasternak GW, Hahn EF (1980) Long-acting opiate agonists and antagonists: 14-Hydroxydihydromorphinone hydrazones. J Med Chem 23: 674–676PubMedCrossRefGoogle Scholar
  24. Paterson SJ, Robson LE, Kosterlitz HW (1984) Opioid receptors. In: Udenfriend S, Meienhofer J (eds) The peptides, vol 6. Academic, New York, pp 147–187Google Scholar
  25. Portoghese PS (1970) Relationship between stereostructure and pharmacological activities. Annu Rev Pharmacol 10: 51–76PubMedCrossRefGoogle Scholar
  26. Portoghese PS (1987) Bivalent ligands in the development of selective opioid receptor antagonists. In: Mutschler E, Winterfeldt E (eds) Trends in medicinal chemistry. VCH, Weinheim, pp 327–336Google Scholar
  27. Portoghese PS (1989) Bivalent ligands and the message-address concept in the design of selective opioid antagonists. Trends Pharmacol Sci 10: 230–235PubMedCrossRefGoogle Scholar
  28. Portoghese PS, Takemori AE (1985) TENA, a selective kappa opioid receptor antagonist. Life Sci 36: 801–805PubMedCrossRefGoogle Scholar
  29. Portoghese PS, Larson DL, Say re LM, Yim CB, Ronsisvalle G, Tam SW, Takemori AE (1986) Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J Med Chem 29: 1855–1861Google Scholar
  30. Portoghese PS, Lipkowski AW, Takemori AE (1987) Binaltorphimine and norbinaltorphimine, potent and selective к-opioid receptor antagonists. Life Sci 40: 1287–1292PubMedCrossRefGoogle Scholar
  31. Portoghese PS, Sultana M, Takemori AE (1988a) Naltrindole, a highly selective and potent non-peptide 5-opioid receptor antagonist. Eur J Pharmacol 146: 185–186PubMedCrossRefGoogle Scholar
  32. Portoghese PS, Sultana M, Nagase H, Takemori AE (1988b) The message-address concept in the design of highly potent and selective opioid receptor antagonists. In: Melchiorre C, Gianella M (eds) Recent advances in receptor chemistry. Elsevier, Amsterdam, pp 307–317Google Scholar
  33. Portoghese PS, Sultana M, Takemori AE (1988c) Application of the message-address concept in the design of highly potent and selective non-peptide 5- opioid receptor antagonists. J Med Chem 31: 281–282PubMedCrossRefGoogle Scholar
  34. Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE (1988d) Binaltorphimine-related bivalent ligands and their K opioid receptor antagonist selectivity. J Med Chem 31: 836–841PubMedCrossRefGoogle Scholar
  35. Portoghese PS, Nagase H, Takemori AE (1988e) Only one pharmacophore is required for the K opioid antagonist selectivity of norbinaltorphimine. J Med Chem 31: 1344–1347PubMedCrossRefGoogle Scholar
  36. Portoghese PS, Sultana M, Takemori AE (1990) Design of peptidomimetic 8 opioid receptor antagonists using the message-address concept. J Med Chem 33: 1714–1720PubMedCrossRefGoogle Scholar
  37. Portoghese PS, Nagase H, MaloneyHuss KE, Lin C-E, Takemori AE (1991) Investigation of the spacer and address components in 5 opioid antagonists related to naltrindole. J Med Chem 34: 1715–1720PubMedCrossRefGoogle Scholar
  38. Renugopalakrishnan V, Rapaka RS, Bhargava HN (1990) Conformational features of opioid peptides: ligand-receptor interactions. In: Szekely J, Ramabadran K (eds) Biochemistry and applied physiology. CRC Press, Boca Raton, pp 53–114 (Opioid peptides, vol 4 )Google Scholar
  39. Sawynok J, Pinsky C, LaBella FS (1979) Minireview on the specificity of naloxone as an opiate antagonist. Life Sci 25: 1621–1632PubMedCrossRefGoogle Scholar
  40. Schild HO (1957) Drug antagonism and pAx. Pharmacol Rev 9: 242–246PubMedGoogle Scholar
  41. Schiller P (1984) Conformational analysis of enkephalin and conformation-activity relationships. In: Udenfriend S, Meienhofer J (eds) The peptides, vol 6. Academic, New York, pp 219–268Google Scholar
  42. Schmidhammer H, Burkhard WP, Eggstein-Aeppli L, Smith CFC (1989) Synthesis and biological evaluation of 14-alkoxymorphinans: 2. (-)-N-(cyclopropylmethyl)- 4,14-dimethoxymorphinan-6-one, a selective μ opioid receptor antagonist. J Med Chem 32: 418–421PubMedCrossRefGoogle Scholar
  43. Schwyzer R (1977) ACTH: a short introductory review. Ann NY Acad Sci 297: 3–26PubMedCrossRefGoogle Scholar
  44. Smits SE, Takemori AE (1970) Quantitative studies on the antagonism by naloxone of some narcotic-antagonist analgesics. Br J Pharmacol 39: 627–638PubMedGoogle Scholar
  45. Sofuoglu M, Portoghese PS, Takemori AE (1991) Differential antagonism of delta opioid agonists by naltrindole (NTI) and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther (in press)Google Scholar
  46. Szmuszkovicz J, von Voigtlander PF (1982) Benzeneacetamide amines: structurally novel non-mu opioids. J Med Chem 25: 1125–1126PubMedCrossRefGoogle Scholar
  47. Takemori AE, Portoghese PS (1984) Comparative antagonism by naltrexone and naloxone of K, and 8 agonists. Eur J Pharmacol 154: 101–104CrossRefGoogle Scholar
  48. Takemori AE, Ho BY, Naeseth JS, Portoghese PS (1988) Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246: 255–258PubMedGoogle Scholar
  49. Tallarida RJ, Cowan A, Adler MW (1979) pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci 25:637–654PubMedCrossRefGoogle Scholar
  50. Yoneda S, Kitamura K, Doi M, Inoue M, Ishida T (1988) Importance for folded monomer and extended antiparallel dimer structures as enkephalin active conformation. FEBS Lett 239: 271–275PubMedCrossRefGoogle Scholar
  51. Zimmerman DM, Leander JD (1990) Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J Med Chem 33: 895–902PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • P. S. Portoghese

There are no affiliations available

Personalised recommendations